RxDoctor Payments Data

Colten Stokes, PA

Physician Assistant · Ogden, UTNPI 1336619402

Payments from drug & device makers

$1,109in general payments, 2019–2025

Across 42 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$490
  • E.r. Squibb & Sons, L.L.C.$130
  • Intercept Pharmaceuticals, Inc.$114
  • Regeneron Healthcare Solutions, Inc.$110
  • Bristol Myers Squibb$92
  • Takeda Pharmaceuticals U.S.A., Inc.$76
  • plus $98 from 3 others

What the payments were for

  • Food & beverage$1,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,109 in reported general payments places this provider in the 70th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$26,110
Medicare patients
168
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase24$46,091
XifaxanRifaximin13$36,106
LinzessLinaclotide45$26,584
TrulancePlecanatide32$22,573
ViberziEluxadoline12$17,724
SutabSod Sulf/Pot Chloride/Mag Sulf41$6,921
MovantikNaloxegol Oxalate13$4,496
Colestipol Hcl49$3,828
Lubiprostone38$3,251
Omeprazole104$1,984
Pantoprazole Sodium113$1,788
Famotidine85$1,782
Balsalazide Disodium14$1,723
Sucralfate42$1,562
Esomeprazole Magnesium23$1,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$490$90,40081 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$44$58,67945 claims
Braintree Laboratories, Inc.Sutab$33$6,92141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →